Coldstream Capital Management Inc. Increases Stock Position in Agilent Technologies, Inc. (NYSE:A)

Coldstream Capital Management Inc. raised its position in Agilent Technologies, Inc. (NYSE:A) by 6.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,479 shares of the medical research company’s stock after buying an additional 280 shares during the period. Coldstream Capital Management Inc.’s holdings in Agilent Technologies were worth $660,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Menard Financial Group LLC grew its stake in Agilent Technologies by 1.6% in the 2nd quarter. Menard Financial Group LLC now owns 4,845 shares of the medical research company’s stock valued at $628,000 after acquiring an additional 77 shares during the period. McAdam LLC grew its position in shares of Agilent Technologies by 3.1% in the third quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock valued at $376,000 after purchasing an additional 77 shares during the period. Brown Brothers Harriman & Co. increased its stake in shares of Agilent Technologies by 13.5% during the third quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after purchasing an additional 77 shares in the last quarter. Global Retirement Partners LLC raised its position in shares of Agilent Technologies by 3.2% during the 3rd quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock worth $382,000 after purchasing an additional 79 shares during the last quarter. Finally, Rovin Capital UT ADV lifted its stake in Agilent Technologies by 1.6% in the 3rd quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock valued at $750,000 after buying an additional 81 shares in the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.

Agilent Technologies Trading Down 1.3 %

A opened at $139.05 on Friday. The stock has a market capitalization of $39.95 billion, a PE ratio of 31.46, a P/E/G ratio of 4.48 and a beta of 1.07. Agilent Technologies, Inc. has a one year low of $124.16 and a one year high of $155.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.58 and a current ratio of 2.09. The business’s 50 day moving average price is $136.75 and its 200 day moving average price is $136.52.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.41 by $0.05. The business had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The company’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.38 EPS. As a group, equities research analysts expect that Agilent Technologies, Inc. will post 5.56 EPS for the current year.

Agilent Technologies Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 22nd. Stockholders of record on Tuesday, December 31st will be paid a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.71%. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Tuesday, December 31st. Agilent Technologies’s payout ratio is 22.40%.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. This represents a 19.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on A. Wells Fargo & Company reduced their target price on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a report on Monday, December 9th. Bank of America reduced their price objective on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research note on Friday. UBS Group upped their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. Evercore ISI increased their target price on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Finally, TD Cowen boosted their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Agilent Technologies presently has a consensus rating of “Hold” and an average price target of $143.62.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.